返回 
加入收藏
克拉霉素强化治疗用于慢性鼻窦炎患者的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 克拉霉素强化治疗用于慢性鼻窦炎患者的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨克拉霉素强化治疗用于慢性鼻窦炎患者的疗效、安全性及对血清炎性细胞因子的影响。方法：186例慢性鼻窦炎患者随机分为对照1组（62例）、对照2组（62例）和观察组（62例）。对照1组患者口服阿莫西林克拉维酸钾片（7 ∶ 1）0.457 g，每日3次；对照2组患者口服克拉霉素分散片0.25 g，每日1次；观察组患者口服克拉霉素分散片第1周0.5 g，每日2次，第2周0.25 g，每日2次。各组患者疗程均为2周。观察各组患者的临床疗效和治疗前后各临床症状评分、肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）、超敏C反应蛋白（hs-CRP）水平及不良反应发生情况。结果：总有效率观察组（93.55％）＞对照2组（80.65％）＞对照1组（65.51％），差异均有统计学意义（P＜0.05）。治疗前，各组患者各临床症状评分、TNF-α、IL-6、hs-CRP水平比较，差异均无统计学意义（P＞0.05）；治疗后，各组患者各临床症状评分、TNF-α、IL-6、hs-CRP水平均显著低于同组治疗前，且观察组＜对照2组＜对照1组，差异均有统计学意义（P＜0.05）。观察组、对照2组患者不良反应发生率均显著低于对照1组，差异均有统计学意义（P＜0.05），但观察组与对照2组间比较，差异无统计学意义（P＞0.05）。结论：克拉霉素强化治疗用于慢性鼻窦炎的疗效显著，可改善患者的临床症状，降低血清炎性细胞因子水平，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To investigate therapeutic efficacy and safety of clarithromycin intensive therapy on patients with chronic rhinosinusitis and its effects on serum inflammatory cytokines. METHODS： A total of 186 patients with chronic rhinosinusitis were randomly divided into control group 1 （62 cases）， control group 2 （62 cases） and observation group （62 cases）. Control group 1 was given Amoxicillin and clavulanate potassium tablet （7 ∶ 1） 0.457 g， 3 times a day. Control group 2 was given Clarithromycin dispersible tablet 0.25 g orally， once a day. Observation group was given Clarithromycin dispersible tablet 0.5 g orally on the first week， twice a day， 0.25 g at the second week， twice a day. Both groups were treated for 2 weeks. Clinical efficacies of 3 groups were observed. Clinical symptom score， TNF-α， IL-6 and hs-CRP before and after treatment as well as the occurrence of ADR were observed. RESULTS： Total response rate was in descending order： observation group （93.55％）＞control group 2 （80.65％）＞control group 1（65.51％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in clinical symptom score， the levels of TNF-α， IL-6 and hs-CRP among 3 groups （P＞0.05）. After treatment， clinical symptom score， the levels of TNF-α， IL-6 and hs-CRP were significantly lower than before treatment； those indexes of 3 groups were in ascending order： observation group＜control group 2＜control group 1， with statistical significance （P＜0.05）. The incidence of ADR in observation group and control groups were significantly lower than control group 1， with statistical significance （P＜0.05）. There was no statistical significance between observation group and control group 2 （P＞0.05）. CONCLUSIONS： Clarithromycin intensive therapy shows significant therapeutic efficacy for chronic rhinosinusitis， improves clinical symptoms of patients and reduces the level of serum inflammatory factor without increasing the occurrence of ADR. |
| 期刊： | 2017年第28卷第30期 |
| 作者： | 李震，张瑞桐，苏光春，王莹，周成，刘永刚 |
| AUTHORS： | LI Zhen，ZHANG Ruitong，SU Guangchun，WANG Ying，ZHOU Cheng，LIU Yonggang |
| 关键字： | 慢性鼻窦炎；克拉霉素；强化治疗；炎性细胞因子；疗效；安全性 |
| KEYWORDS： | Chronic rhinosinusitis； Clarithromycin； Intensive therapy； Inflammatory cytokines； Therapeutic efficacy； Safety |
| 阅读数： | 837 次 |
| 本月下载数： | 7 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
